• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Ocular Therapeutix touts data from phase III trial of Dextenza

January 4, 2017 By Sarah Faulkner

Ocular Therapeutix touts data from phase III trial of DextenzaOcular Therapeutix (NSDQ:OCUL) touted interim data today from its phase III trial of Dextenza for the treatment of post-surgical ocular inflammation and pain. The bioresorbable intracanalicular hydrogel plug is designed to release drugs at the ocular surface for up to 30 days.

The company announced last month that Dextenza met the trial’s 2 primary efficacy endpoints: absence of ocular pain after 8 days and lack of inflammation after 2 weeks compared to a placebo. Bedford, Mass.-based Ocular said today that the dexamethasone insert also met its secondary endpoint of absence of ocular flare in the anterior chamber when compared to a placebo. Nearly half of patients in the Dextenza treatment arm had an absence of anterior chamber flare after 4 days following insertion.

The company also reported differences in the absence of anterior chamber cells and ocular pain on days 2, 4, 14 and 30. No serious adverse events related to treatment have been reported throughout the phase III trial, according to the company.

“The positive results for the secondary endpoint of absence of ocular flare build upon the successful topline results from this trial which we announced last month,” chief medical officer Dr. Jonathan Talamo said in prepared remarks. “Ocular flare occurs when the protein content of the aqueous humor increases due to intraocular inflammation, so the fact that we are seeing a statistically significant decrease in the absence of flare across all time points further supports the efficacy profile of Dextenza.”

In July last year, the FDA denied approval for Dextenza, citing “deficiencies in manufacturing process and controls” which were identified during a pre-new drug application approval inspection of its manufacturing facility..

Shares in the company surged in November last year, when the company reported it will soon re-submit its new drug application to the FDA.

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Hydrogels, Optical/Ophthalmic, Regulatory/Compliance, Wall Street Beat Tagged With: Ocular Therapeutix

IN CASE YOU MISSED IT

  • Medtronic to invest $50M in India Diabetes center
  • Flat Medical partners with Mercury Medical on smart syringe distribution
  • Glucotrack to effect a reverse stock split
  • Medtronic unveils ‘MiniMed’ as name for soon-to-be separated Diabetes unit
  • Insulet, Marvel collab to unveil comic book hero with type 1 diabetes

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS